Advancing NAMs for Risk Assessment: Perspectives from SOT 2025 
Paul Locke Paul Locke

Advancing NAMs for Risk Assessment: Perspectives from SOT 2025 

By Breanne Kincaid | April 17th, 2025

Together, these presentations illustrate a clear shift towards integrated, mechanistically informed risk assessment strategies that reduce the number of animals required to generate toxicity data—paving the way for regulatory frameworks that are both scientifically robust and economically sustainable.”

Image by Breanne Kincaid

Read More
Organoid’s Potential to Advance Low Dose Research
Paul Locke Paul Locke

Organoid’s Potential to Advance Low Dose Research

By Loza Taye | April 3rd, 2025

Organoids will have an increasingly important role in shaping our understanding of radiation biology and in the development of policies and medical practices concerning radiation exposure.”

Image by aislan13

Read More
The Utility of an Intra-Agency NAM Office
Paul Locke Paul Locke

The Utility of an Intra-Agency NAM Office

By Breanne Kincaid | January 10th, 2025

“…the FDA’s NAM office represents a strategic evolution in integrating innovative methodologies into regulatory science. While it complements ICCVAM’s mission, its intra-agency focus and regulatory authority position it to drive faster, more context-specific advancements in risk assessment.“

Read More
Professional Perspectives: Swiss Court Prohibits Zebra Finch Experiment
Paul Locke Paul Locke

Professional Perspectives: Swiss Court Prohibits Zebra Finch Experiment

By Katerina Stoykova and Nicole Lüthi | October 17th 2024

“The harm-benefit analysis is a legal requirement under Swiss experimentation law, stipulating that animal experiments are only allowed if the anticipated benefits outweigh the stress inflicted on the animals. The more severe the stress caused by an experiment, the greater the expected benefit must be to justify it.”

Read More
Regulation Updates in China
Paul Locke Paul Locke

Regulation Updates in China

By Yiguang Zhu and Zachary Leibowitz | August 22nd, 2024

“A wave of regulatory updates in China is reshaping the landscape of the field of animal testing, challenging long-standing practices and opening doors to innovative non-animal alternatives.”

Read More